Alexia Kieffer

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.

Journal: Expert review of vaccines

Published: November 18, 2025

Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infants.

Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infants.

Journal: Human vaccines & immunotherapeutics

Published: April 05, 2025

Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection.

Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection.

Journal: PharmacoEconomics

Published: January 19, 2025

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan.

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan.

Journal: Infectious diseases and therapy

Published: October 22, 2024

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy.

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy.

Journal: Global & regional health technology assessment

Published: June 27, 2024

Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes.

Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes.

Journal: Infectious diseases and therapy

Published: May 06, 2024

Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.

Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.

Journal: BMC infectious diseases

Published: December 12, 2023

Correction: Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018.

Correction: Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018.

Journal: BMC infectious diseases

Published: February 28, 2023

Response to Fullarton et al.

Response to Fullarton et al.

Journal: The Journal of infectious diseases

Published: December 12, 2022

Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.

Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: August 22, 2022

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.

Journal: The Journal of infectious diseases

Published: August 15, 2022

Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model.

Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model.

Journal: Infectious diseases and therapy

Published: August 23, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026